Tech Company Financing Transactions
OptiNose Funding Round
On 8/5/2014, OptiNose secured Series C funding from Avista, Entrepreneurs Fund and WFD Ventures.
Transaction Overview
Company Name
Announced On
8/5/2014
Transaction Type
Venture Equity
Amount
Unknown
Round
Series C
Investors
Proceeds Purpose
With this latest round of financing, we are well-positioned to take the actions necessary to maximize the potential of our second product, OPN-375, which we believe will be a transformational breakthrough product in a large market with significant unmet need.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
1020 Stony Hill Rd. 300
Yardley, PA 19067
USA
Yardley, PA 19067
USA
Phone
Website
Email Address
Overview
Optinose (Nasdaq: OPtN) creates drug delivery technologies that in essence make good drugs better. We hope to accomplish this by taking aim at one of the healthcare industry's greatest challenges: to efficiently and reliably deliver drugs to targeted, hard to reach areas of the body in order to treat medical conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Miller
Chief Operating Officer
Ramy Mahmoud
Chief Scientific Officer
Per Djupesland
VP - Bus. Development
John Messina
VP - Finance
Michele Janis
VP - Regulatory Affairs
Ramona Lloyd
Browse more venture capital transactions:
Prev: 8/5/2014: FlexWage Solutions venture capital transaction
Next: 8/6/2014: Andrew Alliance venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs